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An Educational Module on Post-Operative Nausea & Vomiting Prevention Using Haldol
Postoperative nausea and vomiting (PONV) is the most common side effect of patients
receiving anesthesia. These outcomes are seen both shortly after and within 24 hours of a
surgical procedure. PONV rates among surgical candidates can be as high as 30%.1 There are
many drug combinations anesthesia providers utilize to prevent PONV, including Reglan,
Zofran, Decadron, Scopolamine, Emend, and Propofol to some degree. However, anesthesia
providers do not commonly give Haldol to patients intra-operatively, even though it contains
both anti-nausea and anti-vomiting properties. The purpose of this paper is to educate anesthesia
providers on the benefits of incorporating Haldol in their patient treatment plans to help prevent
PONV.
Background
PONV is a serious issue that many healthcare institutions have been trying to solve.2
Enhanced Recovery After Surgery (ERAS) protocols have been created to accomplish this goal,
given the widespread number of patients affected by PONV. ERAS protocols are evidence-based
recommendations written to improve surgical outcomes. There are approximately 20 focus areas,
with PONV being one of them. ERAS protocols promote a multi-modal approach to prevent
PONV. Antiemetic administration, total intravenous anesthesia (TIVA), and less volatile agent
usage are a few examples of ERAS recommendations designed to minimize PONV.3 In
conjunction with ERAS, various assessment tools are available to determine patient risk factors
that influence their susceptibility to PONV. A commonly used tool3 is the Apfel score,
comprised of 4 high-risk categories: female gender, a history of PONV/motion sickness, nonsmoking status, and the use of post-operative opioids. The more items on this list that a patient
meets, the greater their PONV risk. Patients who meet 1-2 risk factors receive 2 antiemetics, and

3
patients with higher risk factors receive 2-3 antiemetics.3 The Apfel tool creates awareness for
anesthesia providers to effectively formulate a treatment plan to combat PONV for at-risk
patients. Authors Nagelhout and Elisha3 make mention of an expanded PONV at-risk list that
includes: female gender, PONV history, non-smokers, age less than 50 years old, use of volatile
anesthetic agents, use of nitrous oxide, opioid use post-operatively, and length of exposure to
anesthesia during a given procedure.
Scope of the Problem
More than 21 million surgeries were performed in the United States in 2014.4 Globally,
this number increases exponentially. PONV can be an unfortunate consequence for any patient
who undergoes a surgical procedure. Research3 demonstrates that up to 30% of surgical patients
experience PONV. However, other peer-reviewed journals and anesthesia textbooks claim this
number may be as high as 80% depending on patient risk factors and co-morbidities.3,5
Moreover, specific procedures such as breast, gynecological, and open heart surgeries can carry a
PONV risk as high as 70%.6
In an observational study,7 healthcare staff noticed patients experiencing PONV less than
half of the time in the post-anesthesia care unit (PACU). Depending on the demands of the
hospital and staffing issues, patients may be overlooked and not receive the necessary care to
address their PONV needs. For example, the current COVID-19 pandemic has forced healthcare
facilities to divert staff and other resources, which negatively impacts care and attention patients
need for recovery and timely discharge.4
Consequences of the Problem
The consequences of PONV, or lack of prophylactic treatment, can lead to a myriad of
issues. Research8 shows that patients attribute pain as a subsequent outcome when they
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experience PONV symptoms. Moreover, patients consider PONV more concerning and stressful
than pain post-operatively.8 Additional patient concerns associated with unwanted side effects
from PONV exist as well. The act of emesis, for example, raises intracranial pressure and
reduces cerebral perfusion necessary for brain function.8 PONV can lead to aspiration with
emesis contents, and/or dehydration, as well as electrolyte and acid-base balances.2,8 The
consequences of PONV can manifest in many undesirable ways and negatively affect patient
health and recovery.
PONV can also lead to discharge delays from the PACU and the hospital.7,2 Among
bariatric patients, PONV is the most common cause of unplanned hospital readmission.2 One
study concluded that the incidence of PONV among patients increased PACU stays by at least 1
hour.8 The cost to the healthcare system due to PONV within the United States amounts to
approximately between $253 270 and $519 617 annually.8 These outcomes can be minimized or
avoided with the use of anti-emetics such as Haldol.
Knowledge Gaps
ERAS recommendations, specifically related to PONV, have been put forth to guide
anesthesia providers’ plan of care. A review of the literature supports ERAS protocols and touts
its many successes regarding improving patient care. Despite this, ERAS and other similar tools
have not been readily accepted nor implemented across healthcare institutions.9 This knowledge
gap directly contributes to the lack of its adoption and the use of Haldol as a PONV remedy.
Furthermore, anesthesia providers associate Haldol as a means to treat psychotic
disorders, not necessarily PONV. Haldol has side effects that may include dystonia or tardive
dyskinesia, which anesthesia providers want to avoid when possible.10 Additionally, the United
States Food and Drug Administration (FDA) has issued a “Black Box” warning since Haldol is
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associated with a prolonged QT interval, which is the depolarization and repolarization of the
heart’s ventricles.8,10,11 However, all these effects are seen only when Haldol is administered in
doses equal to or greater than 2mg.11 The lack of awareness associated with its PONV benefits
and proper dosing to avoid its side effects impedes Haldol’s use in the clinical setting.
Proposal Solution
Haldol can be used to treat psychotic disorders, it causes sedation, and it contains antinausea and anti-vomiting properties, all of which are beneficial anesthesia outcomes. It is
classified as a butyrophenone that antagonizes the dopamine 2 (D2) receptor. When triggered,
the D2 receptor is known to induce nausea and vomiting in the chemoreceptor trigger zone
(CTZ).12 Therefore, stopping this process is beneficial, especially during and after surgical
procedures. Haldol has an extended half-life and its anti-nausea and anti-vomiting mechanism
can last 24 hours.11 Haldol also seems to intensify the analgesic properties of opiates so that
fewer narcotics are needed.13 This aligns well to reduce PONV and works synergistically with
ERAS recommendations. The literature does recommend 0.5mg - 1mg for PONV to avoid
dystonia or tardive dyskinesia.9
Literature Review
Objective
The literature review’s purpose is to explore previous research on anesthesia provider
knowledge, attitude, and skill in treating PONV. The literature review’s secondary goal is to
analyze available evidence-based guidelines that focus on preventing PONV. Finally, the focus
of the literature review transitions to the review of Haldol as a specific treatment for PONV to
improve patient outcomes.
Methodology
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Eligibility Criteria
Research articles appraised for this literature review were selected based on various
inclusion and exclusion criteria. Inclusion criteria were studies published from 2017 to 2021,
English language, peer-reviewed, and full-text only. Exclusion criteria included studies with
subjects younger than 18 years of age. Florida International University’s (FIU) library database
was utilized to access the articles for the literature review. The databases utilized for the search
included CINAHL, MEDLINE, PubMed, Gale OneFile, DOAJ Directory of Open Access
Journals, Wiley Online Library Database Model 2019, and ScienceDirect Journals. The
literature review was further guided by the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA). Based on the clinical question, the following search keywords
were identified: Haldol, Haloperidol, PONV, postoperative nausea and vomiting, ERAS, and
enhanced recovery after surgery.
Search Strategy
Boolean search techniques were applied and included “(Haldol OR Haloperidol) AND
(PONV OR “postoperative nausea and vomiting”)”. This initial search yielded 600 results. Of
these, 399 were peer reviewed articles, 376 English language articles, 113 were published within
the last 5 years, and 3 shared the exact title match. A second Boolean search was conducted and
consisted of “(Haldol OR Haloperidol) AND (ERAS OR “enhanced recovery after surgery”)”.
This search returned 2145 results with 1629 being peer review, 1608 written in the English
language, 322 dated in the last 5 years, and 1 with an exact title match. The third Boolean search
used was “(Haldol OR Haloperidol) AND (“general anesthesia” OR GA)” and returned 9779
results. The results were further parsed with 7994 being peer reviewed, 7795 written in the
English language, 1328 written within the last 5 years, and 7 exact title matches. The final
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Boolean search applied was “(Haldol OR Haloperidol) AND (“postoperative” OR “Post-op” OR
Postop)” and 58 results were returned. Of the 58 articles, 35 were peer reviewed, 33 written in
the English language, 7 articles created within the last 5 years, and 7 with an exact title match.
A total of 53 articles were reviewed and selected for a more in-depth abstract review. Of
the 53 articles, 8 articles met the full criteria and were further reviewed. Articles that were
removed in this process included those that focused on patients younger than 18 years old. Only
the articles that fully met the criteria were designated appropriate for the literature review.
Table 1. Search Keywords
Boolean
Search
Criteria
(Haldol OR
Haloperidol)
AND (PONV
OR
“postoperative
nausea and
vomiting”
(Haldol OR
Haloperidol)
AND (ERAS
OR “enhanced
recovery after
surgery")
(Haldol OR
Haloperidol)
AND (“general
anesthesia” OR
GA)
(Haldol OR
Haloperidol)
AND
(“postoperative”
OR “Post-op”
OR Postop)

Results

Peer
Reviewed

English
Language

Last 5
Years

Exact Title
Match

600

399

376

113

5

2145

1629

1608

322

1

9779

7994

7795

1328

7

58

35

33

7

7
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Results
Study Characteristics
The 8 articles designated for this literature review examined 2 specific concepts. The first
concept outlines the benefits of using standardized tools that healthcare providers can use for
PONV risk stratification and associated treatment recommendations. Bellizzi et al,5 Stephenson
et al,8 and Jin et al2 all cite advantages when anesthesia providers follow specific PONV facility
protocols to combat PONV. Although the methods by which to accomplish this goal vary,
incidences of PONV were reduced. The second concept focuses on the awareness and benefits of
using Haldol for PONV. Brettner et al,9 Kamali et al,11 Dağ et al,12 Sunil et al,14 and Singh et al10
agree that Haldol is a beneficial drug to reduce the PONV risk. Research methods for the articles
include a retrospective study by Bellizzi et al,5 a prospective cohort study by Stephenson et al,8 a
systematic review by Jin et al,2 a register-based cohort study by Brettner et al,9 randomized
clinical trials by Kamali et al,11 Dağ et al,12 and Sunil et al,14 and meta-analysis and trial
sequential analysis by Singh et al.10
Summary of the Literature
Bellizzi et al5 conducted a retrospective study to analyze PONV protocols within a
specific hospital system and summarized the associated impacts. The authors collected data in
2012 and again in 2017 as a follow-up. Study participants were male and female, 18 years and
older, undergoing elective surgery, and receiving general anesthesia. The authors examined
which patients experienced PONV during their time in the post-anesthesia care unit (PACU) and
who had an unplanned admission afterwards that was due to PONV. Contact was made 72 hours
after surgery to follow up and determine PONV symptoms as well. The data was collected and
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analyzed using various software such as Microsoft Excel and IBM SPSS. Patient eligibility
reached 195 participants in 2012 and 173 in 2017. PONV protocols were not in place in 2012.5
However, in 2017 the Apfel scoring system was introduced and implemented.5 Bellizzi et
al5 discovered that the administration of antiemetics in 2012 was only 27%, compared to 62% in
2017 after the Apfel scoring system was implemented. Results show that antiemetic
administration in 2017 was still problematic as patients were under-prescribed PONV
medications. For example, approximately one-third of patients with an Apfel score greater than
3, considered high-risk, were prescribed the correct dosage of antiemetic medications.
Study limitations were noted by Bellizzi et al.5 Pain is a known contributor to the
perception of nausea and vomiting. Pain assessments were not collected nor analyzed in
conjunction with PONV reporting. Moreover, patient satisfaction scores were not accounted for
to determine treatment success rates. Future recommendations were noted as well. The
importance of creating greater educational awareness was stressed, and creating automated
PONV prophylaxis computer reminders, especially for high-risk surgical procedures, were all
suggested.5
Similar conclusions were made by Stephenson et al8 in a prospective cohort study. The
study spanned 12 months and analyzed PONV data from 500 same-day surgical patients
receiving general anesthesia. The Apfel scoring system was used for each study participant. The
data analysis consisted of the Mann-Whitney U test, the Chi-square, and Fisher's exact test.
Exclusion criteria included chemotherapy patients, palliative care patients with chronic opioid
use, and antiemetic use 24 hours before surgery. Study limitations8 were outlined, and patient
follow-up did not occur post-discharge from the PACU, so the patient population affected by
PONV may be more extensive. This study8 did not include female patients undergoing
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gynecological procedures. These operations were performed in an adjacent building, and
therefore, PONV prevalence rates are likely skewed. Stephenson et al8 identified that PONV is
significantly reduced when a risk stratification system, like Apfel, is used and the correct
administration of antiemetic prophylaxis is dispensed based on these systems approaches. The
authors states this sentiment is supported in research conducted by Kranke et al7 as well. Without
PONV protocols and education on accompanying treatment, it is difficult to prevent or mitigate
PONV.
Jin et al2 reinforce the concept of PONV prevention and provide a systematic literature
review. The study does not include research methods or search criteria; however, the authors
reference various clinical research articles throughout the paper. PONV prevention is a
multipronged approach. It encompasses risk factor assessment, intervention, prophylaxis, and
rescue treatment. The conclusions provided by Jin et al2 support the use of the Apfel scoring
system, noting the largest barrier to PONV management is low healthcare provider compliance.
According to these authors, historically, healthcare providers would administer only 1 antiemetic
for PONV, and in some cases none. Currently, however, there is a movement towards a
multimodal approach for PONV prophylaxis. Recommendations outlined for reducing PONV
were based on various research methods and include: clinical trials, Cochrane reviews and metaanalyses; total intravenous anesthesia (TIVA) approach with propofol; use of Sugammadex
versus neostigmine for neuromuscular blockade reversal; administering 30 mL/kg IV crystalloids
intraoperatively; the use of Dexmedetomidine bolus or infusion; and chemoprophylaxis drugs
such as Aprepitant. Combining medications to combat PONV is recommended, although Jin et
al2 state a lack of consensus on the degree of benefit for each added antiemetic.
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The articles mentioned previosuly2,5,8,9,11,12, establish the importance of creating,
implementing, training, and reinforcing a formal PONV risk scoring system within a facility.
While Jin et al2 provide several common medication combinations to prevent PONV, Brettner et
al9, through the use of a register-based cohort study, specifically explored the use of Haldol for
PONV prevention, an uncommon approach in clinical practice. Brettner et al9 share that
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for
reporting observational studies were used. Interestingly, the Ethics Committee agreed that
informed consent from the participants was unnecessary. Patient information was collected from
7 January 2008 through 19 June 2012, and those who received general anesthesia were 18 years
or older. Study participants were split into 2 groups, those who received 0.5mg Haldol after
induction and those who did not receive any antiemetic for PONV. Exclusion criteria were
patients who received a dose other than 0.5mg of Haldol. The Apfel scoring system established a
base risk score. Chi-square, Mann-Whitney-U, logistic additive model, and statistical software R
were employed as well. A total of 2617 cases were deemed appropriate and analyzed for the
study.9
The research9 concluded that outcomes from 0.5mg of Haldol were affected by gender.
Males were more prone to benefit from the medication and avoid PONV, while females did not
see any appreciable benefit. Moreover, the authors point out that many other studies did not
determine any gender difference outcomes and that Haldol was just as effective in females as
males. Limitations of the study exist; patient documentation was lacking on smoking and PONV
history. Both of these limitations alter the Apfel scoring system and a patient’s PONV risk.9
A randomized control study conducted by Kamali et al11 focused on the use of Haldol for
PONV treatment compared to ondansetron and dexmedetomidine. The study participants were
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composed of 114 patients undergoing an abdominal hysterectomy. These patients were split into
3 groups, with each section receiving either ondansetron 4mg IV, Haldol 2mg IV, or
dexmedetomidine 1µg/kg IV. It was not disclosed to the patients which antiemetic they were
receiving. The data gathered was analyzed with the statistical software SPSS 23. Inclusion and
exclusion criteria are provided by the authors. For example, exclusion criteria encompassed
patients classified by the American Society of Anesthesiologists (ASA) equal to or greater than
risk levels III and IV. Exclusion also included patients under 35 years old or older than 60, with
Parkinson’s disease, with psychiatric disorders, or with a history of chemotherapy.11
Scoring of the results11 measured that vomiting occurred at hours 2, 4, 12, and 24.
Patients did not experience PONV post hour 12 in any section. However, there was a significant
reduction in PONV before hour 12 for the ondansetron group. The authors11 recognize that their
study disagrees with other research and cite Predeep et al,15 who concluded that ondansetron
4mg IV and Haloperidol 2mg IV are equally efficacious in preventing PONV. Further, the
authors11 indicate that for gynecological laparoscopic surgery, all 3 medications are equally
effective.
Brettner et al9 and Kamali et al11 recognize that elements of their research are not wholly
in agreement with their peers, including ideas such as Haldol being less effective for PONV
experienced by females and Ondansetron being a superior medication for PONV in the first 12
hours of administration for abdominal hysterectomies. Dağ et al12 combine these variables and
conducted a randomized control trial with 250 female patients ages 19-70 years, who were
receiving laparoscopic abdominal hysterectomy.
Study participants were split into 5 groups: placebo, haloperidol 2mg, haloperidol 1mg,
haloperidol 0.5mg, and haloperidol 0.25mg.12 The Ramsay sedation scale, Apfel scoring,
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Aldrete’s recovery scale, and Lyles Quality of Recovery survey were used. Postoperatively, heart
rate, systolic and diastolic arterial pressure, sedation level, visual analog scale values, need for
antiemetics, patient satisfaction, and side effects were measured at 30 minutes, and hours 1, 2, 3,
4, 6, 12, and 24. A nurse with no involvement in the study prepared the medications without the
healthcare provider’s knowledge of each patient’s dose of Haldol. Postoperative evaluations
were conducted by healthcare providers who were also not privy to the specifics of each study
group. The data was analyzed and synthesized by means of SPSS 17.0 statistical software,
Kolmogorov-Smirnov test with Lilliefors correction, Kruskal-Wallis test, Mann-Whitney U test,
Monte Carlo test, and the Chi-square test.12
The study12 results revealed that 0.5-2mg could be used safely for the prevention of
PONV and that Haldol doses of 1-2mg led to higher patient satisfaction scores. Furthermore,
Haldol is a cost-effective antiemetic, and patients did not experience extrapyramidal side effects
regardless of the dosage of Haldol administered. Moreover, the authors12 reference a randomized
double-blinded trial16 that assessed whether 1mg of Haldol is non-inferior to 4mg of ondansetron
for PONV in 112 adults undergoing general anesthesia. The outcome of the study revealed that
Haldol is non-inferior to ondansetron.16 Therefore, Haldol’s usage should be considered by
healthcare professionals when dealing with PONV prevention.
Sunil et al14 also favor Haldol as an effective PONV treatment. These authors14 examined
the relationship between Haldol and Granisetron, a 5-HT3 receptor antagonist. Inclusion criteria
consisted of adults ages 18-65 years, ASA classification I-II, and patients who were undergoing
laparoscopic surgery under general anesthesia. Exclusion criteria included patients who were
obese, pregnant, diagnosed with a psychiatric disorder, had taken an antiemetic within 24 hours
of the study, had a chronic cough, or had significant organ disease. The patients were split into 2
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groups of 30. While 1 group received 2mg IV Haldol, the other received 1mg IV Granisetron.
Patients were monitored post-operatively and for the following 24 hours.
Study14 results were analyzed using the unpaired t-test, Chi-square test, and ANOVA
analysis. Based on the analysis, the authors14 concluded that there was no statistically significant
difference between 2mg IV Haldol and 1mg IV Granisetron post-operatively through 24 hours.
Both were effective treatments for PONV; however, Granisetron did produce headaches in 20%
of the patients, a statistically significant finding according to Sunil et al.14
Finally, Singh et al10 continue to provide evidence for the use of Haldol as a prophylactic
PONV medication as previous authors9,11,12,14 have supported. The study10 is a noninferiority
meta-analysis and trial sequential analysis of randomized controlled trials that are compliant with
PRISMA. Two independent reviewers analyzed the research. Databases used include PubMed,
Medline, Science Citation Index, Embase, Scopus, Cochrane Central Register of Controlled
Trials, clinical trials registry, Google scholar, and meta-register of controlled trials for published
articles. Title search words used encompassed, haloperidol postoperative nausea vomiting,
PONV efficacy haloperidol, 5-HT3 receptor antagonists (ondansetron, granisetron, ramosetron,
palonosetron) vs haloperidol, perioperative haloperidol, antiemetic haloperidol QTc. Exclusion
terms were also used and only prospective, randomized control trials were incorporated. Data
was analyzed using Comprehensive Meta-Analysis-Version 3, fixed-effects modeling, randomeffects modeling–based analysis, trial sequential analysis software. Of the 316 articles initially
identified, only 7 were deemed a complete match for full analysis.10
The research10 focus was on comparing Haldol to 5-HT3 antagonists for early and late
PONV results, the need for rescue anti-emetics, and drug effects on QTC prolongation. The
results are comparable and yielded no statistically significant variables. The only exception was
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found with 5-HT3 drug prices being more expensive by approximately 50% on average. Singh et
al10 conclude that Haldol is not inferior to 5-HT3 medications and it should be used on a regular
basis. A summary of the findings is outlined in Table 2, below.
Table 2. Haldol Versus 5-HT311
Drugs

Vomiting
Within 6
Hours

Need for
Rescue Antiemetic
Within 24
Hours

QTc
Price ($)
Prolongation

Haldol

7.65%

18.82%

4.50

5-HT3

5.56%

70 out of 342
patients
75 out of 343
patients

15.82%
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Discussion
Summary of the Evidence
Based on the literature, it has been established that PONV is a significant issue for
patients, healthcare workers, and healthcare facilities attempting to reduce readmission rates and
increase patient satisfaction scores. According to research, with PONV rates as high as 80%,
every viable medication must be considered.3,4 The first step to combat PONV is to ensure that a
proper systematic PONV risk scoring system is in place.5,8,12 The Apfel scoring system is a
frequently used tool within the healthcare space and assigns a PONV risk level based on a
patient’s medical history, gender, and age. Once implemented, adherence to the new scoring
system is vital to ensure at-risk patients are identified so that treatment options can be
considered.
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The next step is to educate healthcare providers on medications based on evidential
research that can mitigate PONV. Haldol is a prime example of a medication that should be used
more to treat PONV in the clinical setting. While Kamali et al11 concluded that Haldol is not as
effective at preventing PONV when compared to other medications for every surgery type, their
research recognized that others15 disagree. Overall, review of the literature2,9,10,12–16 determined
that Haldol is a highly effective anti-nausea and anti-vomiting medication.
This literature review also uncovered anesthesia provider concern with Haldol’s ability to
potentially cause QTc prolongation and dystonia or tardive dyskinesia.8,10,11 While legitimacy of
this viewpoint is not unfounded, it is important to note that these outcomes are either not
statistically significant or the patient was not properly dosed. Moreover, QTc prolongation is
present at approximately the same rate as 5-HT3 medications such as Zofran.8,10 The anesthesia
professional’s choice to avoid Haldol as a medication to prevent PONV is based on a lack of
knowledge. Furthermore, Haldol’s affordable price point is more attractive to healthcare
organizations, and patients, seeking to be more cost conscious.10
Conclusion
Postoperative nausea and vomiting (PONV) continues to remain a serious issue that many
healthcare institutions need to address. For this reason, ERAS protocols have been created to
accomplish this goal, including the use of Apfel scores which can reveal a patient’s PONV risk.
As demonstrated by the evidence, when dosed at 0.5-2mg, Haldol can effectively help prevent
PONV in the clinical setting. Its usage can generate faster discharge times, reduce healthcare
costs, lower opioid use, and increase patient safety and satisfaction. Greater awareness and
education of ERAS protocols, specifically the benefits of Haldol to prevent PONV, are necessary
for greater adoption amongst anesthesia providers.
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PICO Question
The purpose of this quality improvement project is to increase awareness of the benefits
of Haldol in reducing PONV. In translating evidence from the literature into a clinical problem,
the PICO formula has been used to guide this research. As such, the PICO clinical question for
this project is:
•

For anesthesia providers working in an acute care facility (P), does the use of an
educational model regarding the use of Haldol for patients over the age of 18 undergoing
general anesthesia (I), when compared to current treatments (C), increase anesthesia
provider Haldol usage as an ERAS option (O).

When breaking down this question into its respective P, I, C, O elements, the following can
be noted:
•

P: Anesthesia providers working in an acute care facility.

•

I: Education regarding the use of Haldol for patients undergoing general anesthesia.

•

C: Care as usual.

•

O: Increased anesthesia provider adoption of Haldol as an ERAS option.
Goals and Outcomes
To help guide the project to its outcomes, specific, measurable, achievable, relevant, and

time-bound (SMART) goals were used.17
Specific
Anesthesia providers will have ERAS protocols in place for treating PONV, which will
include anesthesia provider education on the use of Haldol for adults undergoing general
anesthesia.
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Measurable
Pre and post-test assessments will be conducted among anesthesia providers to determine
if ERAS protocols were followed, assess anesthesia provider Haldol knowledge, and if Haldol
was used for patients at risk for PONV. The data will be collected, analyzed, and synthesized.
Achievable
Inter-professional collaboration between stakeholders is paramount for the success of this
project. Project champions or leaders will be assigned to help ensure the project’s roll-out is
successful. These individuals will act as knowledge guides should questions arise and they will
help remind stakeholders of the project’s objectives.
Realistic
Anesthesia professionals will be educated on the project’s goals and introductions to the
project leaders will be made prior to implementation. The pre and post-test will be collected and
uploaded into a software system. If electronic charting is used, partnering with nursing
informatics may be necessary to help create system reminders to follow ERAS protocols and
recommend Haldol to treat PONV if a patient meets the project’s criteria.
Timely
Stakeholders will be educated on the project for 2 weeks prior to implementation. Data
will be collected over the course of 6 months from anesthesia professionals. Goal outcomes will
be assessed every 2 weeks to determine if adjustments are required.
Definition of Terms
•

Anesthesia Provider/Anesthesia Professional: Any licensed healthcare personnel who are
able to provide anesthesia medication to patients, such as anesthesiologist, certified
registered nurse anesthetist, physician’s assistant, PACU nurser, or pre-operative nurse.
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•

Postoperative Nausea and Vomiting (PONV): PONV is an undesirable outcome of
general anesthesia that can occur soon after surgery or as late as 24 hours after surgery.1

•

Enhance Recovery After Surgery (ERAS): Protocols put in place by a healthcare facility
to enhance surgical outcomes, promote patient well-being, and reduce costs.16

•

Haldol: A medication classified as a butyrophenone that antagonizes the dopamine 2
receptor. It is used as a treatment for psychotic conditions and it can be used to treat
PONV.12
Theoretical Framework Overview
The Theory of Unpleasant Symptoms (TOUS) is a middle range theory that was first

presented in 1995.18 It focuses on 1 or more symptoms occurring together whereby, treating 1
symptom will lead to downstream modifications and possible prevention of other symptoms.
Symptoms have measurable concepts such as severity timing, distress, and quality. The TOUS
recognizes antecedent factors affecting a patient that an anesthesia provider must consider:
physiological, psychological, situational, and performance factors.18 The anesthesia professional
attempts to discover the cause, treatment methods tried, emotional state, the patient’s life
circumstances, other symptoms present, medical history, and antecedents. Physiologically,
inquiries about past procedures or medications being used could be contributing to unpleasant
symptoms. Psychological exploration could uncover a patient’s history of anxiety that may be
causing unwanted symptoms.18 A complete assessment should yield a holistic picture of the
patient’s situation so that, based on findings, a treatment plan is created.
Theory/Clinical Fit
The TOUS requires an anesthesia provider to evaluate the patient’s background on a
deeper level. If nausea and vomiting are related to recent opioid use for pain by the patient, the
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anesthesia provider should consider the following interventions: advise on non-pharmacological
methods, antiemetic medications, and alcohol avoidance. The anesthesia professional would
expect the outcome of these interventions to reduce or eliminate PONV symptoms and achieve
relief for the patient.
Theory Evaluation
Assessment of symptoms is paramount. Symptoms are subjective; therefore, attention to
psychological, physiological, and situational factors offer a more complete health profile of a
patient. Each patient is unique, and these influences provide data points that guide anesthesia
providers towards a treatment plan. Symptom considerations should be validated in conjunction
with physical examination and diagnostic testing in an attempt to determine the true cause of the
symptoms. The focus on symptoms, versus them simply being used as an indicator of an
underlying cause, is a novel concept within nursing literature.18 Further, implementing a middle
range theory as a blueprint for symptom management is also a nascent approach to patient care.
The issue is that not many healthcare institutions utilize TOUS for patient systems evaluation.18
Theory Operationalization
TOUS can be applied and measured in a variety of different ways. A single symptom or a
multitude of symptoms can be addressed. Additionally, the evaluation of symptoms can be solely
physically centered, or it can be physically and emotionally based. The Fatigue Symptom
Inventory accounts for symptom severity and how much it impedes performance of daily
living.18 If the healthcare provider is interested in measuring performance, observation of
activities is used. The visual analog scale and numeric rating scale are additional tools used to
measure symptom intensity. The Memorial Symptom Assessment Scale accounts for physical
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and psychological symptoms.18 These are some of the many tools available to healthcare
providers when employing the TOUS.
Theory Application
The TOUS was originally used to address childbearing fatigue.18 Since then it has
evolved and is now applied to managing patients with chronic illnesses, cancer, breast-feeding
promotion for inner city mothers, chronic obstructive pulmonary disease, heart failure, gastric
and transplant surgery, multiple sclerosis, Parkinson’s disease, and supporting patients to manage
their symptoms on their own.18 The TOUS has many application usages that can benefit the
healthcare provider and patient.
Theory Performance
Practical use of the TOUS has been successful. Research18 examining fatigue in patients
with stable coronary heart disease using the TOUS discovered that a depressive mood was a
strong determinant of fatigue intensity and hindrance on quality of life. Another application of
the TOUS in a clinical setting involved exploring relaxation training and sleep hygiene education
to treat insomnia in depressed patients. The conclusion supported these techniques as a
compliment or alternative to pharmacological treatments.18
Theory Relationship
The TOUS has a direct relationship with this project’s goal. Patients who experience
PONV, which are unpleasant symptoms, can benefit from this theory’s holistic approach to
performing a comprehensive pre-screen and pre-treat patients who are at risk based on findings.
For example, anesthesia providers should inquire if a patient has a history of PONV and attempt
to uncover what precipitated the episode. Factors such as emotional or surgical stress, anesthesia
side effects, and surgery type, are just a few contributing elements that can lead to PONV.18
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Anesthesia providers can mitigate PONV by using risk assessment tools, such as the Apfel
scoring system, and treat patients with the appropriate types of pharmacological agents.
Additionally, anesthesia professionals should inquire about what tactics historically worked for
the patient when they experienced PONV.
Methodology
Setting and Participants
This study will take place within the Broward Health system in Florida and will include
educating anesthesia providers of patients 18 years and older who are undergoing surgery with
general anesthesia. A wide variety of surgeries are performed at this facility including cardiac,
thoracic, gastrointestinal, genitourinary, and others. The American Society of Anesthesiologists
(ASA) created a risk classification system based on a patient’s comorbidities. Patient ASA
classification of I through IV will be included in this study. Patient exclusion criteria are those
experiencing nausea and vomiting symptoms 24 hours prior to surgery, antiemetic use 24 hours
before surgery, chemotherapy patients, and palliative care patients with chronic opioid use.
Description of Approach and Project Procedures
The initial step to this project is to ensure ERAS protocols are in existence at the facility
and that healthcare professionals adhere to these recommendations. Once this is confirmed,
anesthesia providers will be educated by the author of this paper on the purpose, project design,
and implementation phase and invited to participate in the study. Inter-professional collaboration
between stakeholders is paramount for the success of this project. Project champions or leaders
will be assigned to help ensure the project’s roll-out is successful. These individuals will act as
knowledge guides should questions arise and they will help remind stakeholders of the project’s
objectives. Further, pre and post-test assessments will be conducted among anesthesia providers
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to determine if ERAS protocols were followed, their experience with the use of Haldol, and if
Haldol was used for patients at risk for PONV. The end result should be an increase in provider
knowledge in the use of Haldol as a treatment for PONV.
Protection of Human Subjects
To ensure the protection of human subjects, approval from the Institutional Review
Board (IRB) is necessary prior to project commencement. Anesthesia providers will be informed
of the project’s details. Patient qualifications will be confirmed by the anesthesia provider based
on the project’s criteria via the education provided prior to project commencement. No patient
identifiers will be used for Health Insurance Portability and Accountability (HIPPA) purposes.
Data Collection
For the pre and post-test, a paper form will be created and disseminated to anesthesia
providers to track each patient case. The intent of the form is to streamline data collection in a
uniform manner. It will require the anesthesia provider to complete information about their
understanding of ERAS protocols, education of Haldol to treat PONV, and Haldol’s usage in
practice.
Data Management and Analysis Plan
The paper forms will be collected and reviewed before and after the project. The primary
investigator, clinical mentor, and assignment project faculty member will have access to the data.
Based on the data, it can be determined if there was an increase in provider knowledge of Haldol
as a means to treat PONV and its adoption rate.
Discussion of the Results
Short Message Service (SMS) will be used to stay in touch with anesthesia providers and
address questions as they arise. Barriers to the use of Haldol for PONV prevention will be
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discussed and addressed throughout the project’s implementation phase. Upon project
completion, the final results will be made available to participating anesthesia providers in a
follow up meeting. The participants will have an opportunity to discuss the results and ask
follow-up questions. Project feedback will be encouraged to determine what improvements could
be made for future implementations.
Implications to Advanced Nursing Practice
Evidence-based practices (EBPs) are a systematic method to ensure optimal healthcare
outcomes. It is a sophisticated analytical process that relies on evidence garnered from research
conducted in, or extrapolated from, a clinical setting.19 Further, the Institute of Medicine (IOM)
recognized the importance of EBP within healthcare and instituted that by 2020, 90% of clinical
decisions are to be based on EBP.20 Similarly, the American Association of Colleges of Nursing
(AACN) identified EBP as one of its 9 essential elements.21
ERAS are EBPs that can enhance patient outcomes and reduce healthcare costs for
organizations and patients. Educating anesthesia providers on the use of Haldol meets each of the
aforementioned components. The opportunity to bring attention to a PONV remedy, such as
Haldol as this project has outlined, helps solve a major industry issue.
Advance nursing practitioners play a vital role in improving clinical outcomes and are
expected to be change agents within the healthcare industry. EBP projects such as this align well
with the expected standards of practice for an advanced practicing nurse. Awareness creation via
anesthesia provider education, is the first step to practice transformation.
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Appendix 1: Timeline
Project Tasks
1. Education intervention development
2. Request approval from the IRB
3. Create and send study invites to anesthesia providers
4. Pre-test administration
5. Educational intervention implementation
6. Post-test administration
7. Collect, review, analyze, and organize data
8. Share results in post-study meeting
Diagram 1. Project Timeline

1.Education intervention
development

Week 2-3
1.Request approval from
the IRB

Week 1

1.Create and send study
invites
2.Pre-test administration
3.Educational intervention
implementation

Week 4-6

Week 7-31
1.Post-test administration
2.Collect, review, analyze,
and organize data

1.Share results in poststudy meeting

Week 32
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Appendix 2:
Literature
Matrix
Author(s)

Purpose

Bellizzi et al, Analyze
2020
PONV
protocols
within a
specific
hospital
system and
summarize the
associated
impacts

Methodology/
Research
Design
Retrospective
study
Level III

Intervention(s)/
Measures

Sampling/Setting

The authors examined
which patients
experienced PONV
during their time in the
post-anesthesia care
unit (PACU) and who
had an unplanned
admission after that
due to PONV.

Data collection
occurred in 2012
and again in 2017
as a follow-up.
Patient eligibility
reached 195
participants in 2012
and 173 in 2017.

Contact was made 72
hours after surgery to
follow up to determine
PONV symptoms as
well.
The data was collected
and analyzed using
various software such
as Microsoft Excel
and IBM SPSS.
PONV protocols were
not in place in 2012.

Primary Results
Administration of
antiemetics in 2012 was
only 27% compared to
62% in 2017 after the
Apfel scoring system was
implemented.

Relevant Conclusions
The importance of
identifying at risk
PONV patients and
creating greater
prevention awareness
was stressed.
Creating automated
PONV prophylaxis
computer reminders,
especially for high-risk
surgical procedures,
was suggested.
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Stephenson
et al, 2021

Importance of
implementing
a PONV risk
tool and
standardizatio
n of treatment
protocols

Prospective
cohort study
Level IV

In 2017 the Apfel
scoring system was
introduced and
implemented.
Apfel scoring system
was used to gauge
patient PONV risk.
Patients moniotored
every 30 minutes in
PACU.
Number of PONV
episodes and time
were recored.
Severity of PONV was
recorded via the
Numerical Rating
Scale at least one
minute apart.
Rescue anti-emetics
use, dose, and time
were recorded.
PACU duration was
noted
Data collection
occurred using a
primary investigator
and co-investigators.

Study spanned 12
months.
Analyzed PONV
data from 500
same-day surgical
patients receiving
general anesthesia
from a tertiary care
teaching institute.
Patient follow-up
did not occur postdischarge from the
PACU, so the
patient population
affected by PONV
may be more
extensive.

In general, PONV occurred
in up to 80% of patients
deemed “high risk”.
In this study, PONV was
2.05%- 2.45%.

PONV is significantly
reduced when a risk
stratification system,
like Apfel, is used and
the correct
administration of
antiemetic prophylaxis
is administered based
on these systems
approaches.
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Jin et al,
2021

Brettner et
al, 2016

To educate on
PONV
prevention
which,
encompasses
risk factor
assessment,
intervention,
prophylaxis,
and rescue
treatment.

Systematic
literature review
Level I

Low-dose
Haldol and its
effects on
PONV

Register-based
cohort study
Level IV

Data was analyzed
using Epidata (Version
2.0.7.53) and Stata
(Version 13.1).
The study does not
include research
methods or search
criteria; however,
there are references to
various clinical
research articles
throughout the paper

STROBE guidelines
for reporting
observational studies
were used.
Interestingly, the
Ethics Committee
agreed that informed
consent was
unnecessary from the
participants.

Recommendations
outlined for
reducing PONV
were based on
various research
methods that
include clinical
trials, Cochrane
reviews, and metaanalyses.

2,617 surgical
procedures at an
university hospital.
Patient information
was collected from
January 7th, 2008
through June 19th
2012,

Recommendations outlined
for reducing PONV: Total
intravenous anesthesia
(TIVA) approach with
propofol, use of
Sugammadex versus
neostigmine for
neuromuscular blockade
reversal, adminsitering10–
30 mL/kg IV crystalloids
intraoperatively, use of
Dexmedetomidine bolus or
infusion, and
chemoprophylaxis drugs
such as, Aprepitant.
Female patients 3x risk
versus males for PONV.
12.9% of patients
experienced PACU PONV.
Average PACU stay=
150±83 minutes
No PONV significant
difference between Haldol:
non-Haldol groups
(12.6%:13.2%)

Combining medications
to combat PONV is
recommended.
Lack of consensus on
the degree of benefit
for each added
antiemetic.

0.5mg of Haldol
outcomes were affected
by gender.
Males were more prone
to benefit from Haldol
and avoid PONV,
while females did not
see any appreciable
benefit.
Many other studies did
not determine any
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Kamali et
al, 2018

Dağ et al,
2019

Evaluate the
Randomized
effectiveness
clinical trials
of
Level II
ondansetron,
Haldol, and
dexmedetomid
ine on PONV
post
laparoscopic
cholecystecto
my.

Conclude the
Randomized
most effective clinical trials
does for
Level II
Haldol to
prevent PONV

Study participants
were split into 2
groups, those who
received 0.5mg Haldol
after induction and
those who did not
receive any antiemetic
for PONV
Patients were split into
3 groups, with each
section receiving
either ondansetron
4mg IV, Haldol 2mg
IV, or
dexmedetomidine 1
µg/kg IV.

PONV female: male=
18.5%:7.9%

Taleghani hospital
in Arak.
114 patients
undergoing an
abdominal
hysterectomy.

PONV frequency:
Ondansetron= 10%
Haldol= 40%
Dexmedetomidine= 48%

250 female patients
ages 19-70 years,
who were receiving
laparoscopic
abdominal
hysterectomy.

Patients did not
experience PONV post
hour 12 for any section.
Significant reduction in
PONV before hour 12
for the ondansetron
group. The authors
recognize that their
study disagrees with
other research studying
the same topic.

It was not disclosed to
the patients which
antiemetic they were
receiving.

Study participants
were split into 5
groups: placebo,
haloperidol 2 mg,
haloperidol 1 mg,
haloperidol 0.5 mg,
and haloperidol 0.25
mg.

gender difference
outcomes and that
Haldol was just as
effective in females as
males.

Post-operatively (first 2
hours):
26% of patients in Group I,
4% of patients in Group II,
14% of patients in Group
III, 14% of patients in
Group IV, and 28% of

For gynecological
laparoscopic surgery,
all 3 medications are
equally effective.
0.5-2 mg could be used
safely for the
prevention of PONV
and that Haldol doses
of 1-2mg led to higher
patient satisfaction
scores. Furthermore,
Haldol is a cost-
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patients in Group V
experienced PONV.
2-24 hours:
18% of patients in Group I,
4% of patients in Group II,
2% of patients in Group
III, 6% of patients in
Group IV, and 28%
patients in Group V
experienced PONV.
Sunil et al,
2016

To assess the
difference
between
Haloperidol
and
Granisetron as
a prophylactic
PONV
treatment in
patient
undergoing
laparoscopic
surgery

Randomized
clinical trials
Level II

PONV postoperatively through 24
hours, recovery time,
sedation level, pain
scores, nausea scores,
episodes of vomiting,
drug side effects, need
for rescue antiemetic,
and ECG monitoring
at 10 minute intervals
once drug was
administered.

Single site facility,
adults ages 18-65
years, ASA
classification I-II,
and patients who
were undergoing
laparoscopic
surgery under
general anesthesia.

Recovery time and pain
score not statistically
significant. Gender,
weight, and age shown to
not be statistically
significant factors.

Singh et al,
2018

To evaluate
Haldol versus
5-HT3
antagonists for
PONV and
QTc
prolongation

Noninferiority
Meta-Analysis
and Trial
Sequential
Analysis
Level I

Preferred Reporting
Items for Systematic
Reviews and Metaanalyses (PRISMA)
guidelines used.

Title search words
used encompassed,
haloperidol
postoperative
nausea vomiting,
PONV efficacy
haloperidol, 5-HT3

Vomiting within first 6
hours:
Haldol group= 7.65%
5-HT3 group= 5.56%

effective antiemetic,
and patients did not
experience
extrapyramidal side
effects regardless of the
dosage of Haldol
administered.
Haldol is non-inferior
to ondansetron.
No statistically
significant difference
between 2mg IV
Haldol and 1mg IV
Granisetron postoperatively through 24
hours. Both were
effective treatments for
PONV however,
Granisetron did
produce headaches in
20% of the patients, a
statistically significant
finding.
Haldol is not inferior to
5-HT3 medications and
it should be used on a
regular basis.

Need for rescue anti-emetic Haldol is more cost
within 24 hours:
effective on average
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PICO question format
followed

receptor antagonists
(ondansetron,
granisetron,
Two independent
ramosetron,
reviewers analyzed the palonosetron) vs
research.
haloperidol,
perioperative
Comparing Haldol to
haloperidol,
5-HT3 antagonists for antiemetic
early and late PONV
haloperidol QTc.
results, the need for
rescue anti-emetics,
Exclusion terms
and drug effects on
were also used and
QTC prolongation.
only prospective,
randomized, and
control trials were
incorporated.
Databases used
include Pubmed,
Medline, Science
Citation Index,
Embase, Scopus,
Cochrane Central
Register of
Controlled Trials,
clinical trials
registry, Google
scholar, and metaregister of
controlled trials for
published articles.

Haldol group= 70 out of
342 patients
5-HT3 group= 75 out of
343 patients
QTc prolongation:
Haldol group= 18.82%
5-HT3 group= 15.82%
Price (USD$):
Haldol group= 4.50
5-HT3 group= 10

compared to 5-HT3
medications.
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Full text used.

